Skip to content

Study · Randomized controlled trial · n = 12 · 2017

4 results

Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial.

Khoo J, Hsiang J, Taneja R, Law NM, Ang TL

Diabetes, obesity & metabolism14 Jul 2017Cited by 81 (Europe PMC)

PMID28503750 (opens in a new tab)DOI10.1111/dom.13007 (opens in a new tab)PepBankPUB-28503750
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In obese adults with NAFLD, liraglutide 3 mg reduced body weight, similar to a structured diet and exercise program.

    In plain wordsIn obese adults with fatty liver, liraglutide 3 mg lowered weight about as much as a diet and exercise program.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight change
    Study

    n = 12

    Comparator
    Diet and exercise program
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3 mg daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Both DE and LI groups had significant (P < .01) and similar reductions in weight (-3.5 ± 3.3 vs -3.5 ± 2.1 kg, respectively, P = .72)
    1 context sentence
    Summary · context
    We compared the effects of weight loss induced by the glucagon-like peptide 1-agonist liraglutide with a structured lifestyle intervention in obese adults with non-alcoholic fatty liver disease (NAFLD).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In obese adults with NAFLD, liraglutide 3 mg reduced liver fat fraction, similar to a structured diet and exercise program.

    In plain wordsIn obese adults with fatty liver, liraglutide 3 mg lowered liver fat about as much as a diet and exercise program.

    Peptide
    Liraglutide
    Outcome
    DecreaseLiver fat fraction change
    Study

    n = 12

    Comparator
    Diet and exercise program
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    3 mg daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Both DE and LI groups had significant (P < .01) and similar reductions in weight (-3.5 ± 3.3 vs -3.5 ± 2.1 kg, respectively, P = .72), LFF (-8.9 ± 13.4 vs -7.2% ± 7.1%, P = .70), serum alanine aminotransferase (-42 ± 46 vs -34 ± 27 U/L, P = .52) and aspartate aminotransferase (-23 ± 24 vs -18 ± 15 U/L, P = .53).
    1 context sentence
    Summary · context
    We compared the effects of weight loss induced by the glucagon-like peptide 1-agonist liraglutide with a structured lifestyle intervention in obese adults with non-alcoholic fatty liver disease (NAFLD).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In obese adults with NAFLD, liraglutide 3 mg reduced serum alanine aminotransferase, similar to a structured diet and exercise program.

    In plain wordsIn obese adults with fatty liver, liraglutide 3 mg lowered a liver enzyme (ALT) about as much as a diet and exercise program.

    Peptide
    Liraglutide
    Outcome
    DecreaseSerum alanine aminotransferase change
    Study

    n = 12

    Comparator
    Diet and exercise program
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    3 mg daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Both DE and LI groups had significant (P < .01) and similar reductions in weight (-3.5 ± 3.3 vs -3.5 ± 2.1 kg, respectively, P = .72), LFF (-8.9 ± 13.4 vs -7.2% ± 7.1%, P = .70), serum alanine aminotransferase (-42 ± 46 vs -34 ± 27 U/L, P = .52) and aspartate aminotransferase (-23 ± 24 vs -18 ± 15 U/L, P = .53).
    1 context sentence
    Summary · context
    We compared the effects of weight loss induced by the glucagon-like peptide 1-agonist liraglutide with a structured lifestyle intervention in obese adults with non-alcoholic fatty liver disease (NAFLD).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In obese adults with NAFLD, liraglutide 3 mg reduced serum aspartate aminotransferase, similar to a structured diet and exercise program.

    In plain wordsIn obese adults with fatty liver, liraglutide 3 mg lowered a liver enzyme (AST) about as much as a diet and exercise program.

    Peptide
    Liraglutide
    Outcome
    DecreaseSerum aspartate aminotransferase change
    Study

    n = 12

    Comparator
    Diet and exercise program
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    3 mg daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Both DE and LI groups had significant (P < .01) and similar reductions in weight (-3.5 ± 3.3 vs -3.5 ± 2.1 kg, respectively, P = .72), LFF (-8.9 ± 13.4 vs -7.2% ± 7.1%, P = .70), serum alanine aminotransferase (-42 ± 46 vs -34 ± 27 U/L, P = .52) and aspartate aminotransferase (-23 ± 24 vs -18 ± 15 U/L, P = .53).
    1 context sentence
    Summary · context
    We compared the effects of weight loss induced by the glucagon-like peptide 1-agonist liraglutide with a structured lifestyle intervention in obese adults with non-alcoholic fatty liver disease (NAFLD).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.